Participated · Series A · Aug 2022

Oxwash provides low‑temperature commercial and on‑demand laundry using a gentle wet‑cleaning technique with biodegradable detergents, ozone disinfection and reduced water consumption, operated from centralized hub “lagoons.” The company serves both businesses and individuals, with B2B customers including hotels, hospitals, universities, hospitality and circular fashion outlets as well as individual users. Its service is available in five UK cities and it currently operates three washing facilities; Oxwash says it has 20,000+ customers, quadrupled revenue in the past 12 months and has achieved operational profitability across its three facilities. Founded in 2017, the company recently gained B Corporation status and emphasizes employee conditions (riders and couriers are fully employed and staff are paid above the national living wage). Future plans funded by the round include building a large centralized processing facility to enable nationwide U.K. coverage, launching in the U.S. and further European expansion, and investing in next‑gen automation such as acoustic drying, robotics, computer vision and AI. Oxwash employs over 80 people and expects a 50% headcount increase in the next year, and has a stated goal of eliminating scope 1 greenhouse gas emissions from operations within 12 months. Oxwash provides a sustainable on-demand laundry service that aims to achieve net-zero carbon emissions across collection, washing and delivery. The company uses water-saving ozone technology to sterilize fabrics at lower temperatures, thermal and biodegradable chemical processes for higher-than-medical-grade disinfection, dissolvable laundry bags and electric cargo bikes for hyper-local pickups and deliveries. Founded in 2018 by ex-NASA scientist Dr Kyle Grant and Oxford engineer Tom de Wilson, Oxwash now serves more than 8,000 individual customers and enterprise clients including the Marriott Hotel Group, Hurr Collective and the NHS. Oxwash raised an additional £2.08M in seed funding, bringing total funding to £5.2M to date. The company intends to use the funds to expand the team, invest in proprietary technology and accelerate plans for national expansion. It also participated in Collective Impact, a five-week investment-readiness program delivered by Crowdcube and Virgin StartUp for purpose-led businesses. Oxwash, founded in 2017 by former NASA scientist Kyle Grant and based in London, is a sustainable on-demand laundry and dry-cleaning startup. It uses proprietary ozone-generation technology alongside thermal and chemical processes to deliver pharmaceutical-grade disinfection and aims for zero net carbon emissions across collection, washing, and delivery. Customers include consumers, hotels, gyms, and Airbnb hosts, and the company has expanded into healthcare clients such as the NHS, GP practices, care homes, vulnerable people at home, and hotels housing key workers. Oxwash provides coronavirus (COVID-19) disinfection laundry methods and is supplying services to the Oxford University coronavirus vaccine trial. The company is using the newly raised funds to launch into London, further invest in its proprietary technology platform, and expand into North America and Europe over the next 12–18 months. Its funding position is supported by a £1.75M seed round from strategic and angel investors, and an RB Ventures executive will join the board. Oxwash applies 'space-age' sterilisation technology—combining ozone disinfection with thermal and chemical processes—to deliver medical-grade laundry services that remove bacterial, fungal and viral agents. The company says its process achieves zero carbon emissions and saves water compared with traditional laundry options. A product of Oxford University and part of Founders Factory’s accelerator, Oxwash was founded by a former NASA engineer and is led by CEO Kyle Grant. It already serves business customers including Marriott and Airbnb and partners with NHS bodies, senior care homes, hotels housing medical workers, the Oxford University coronavirus vaccine trial and general practice surgeries. During the COVID-19 pandemic Oxwash added no-contact pickups, electric-cargo bikes fitted with portable ozone generators, and dissolvable laundry bags to reduce transmission. The company raised £1.4 million and says the funding will be used to grow the team, expand across southeast England, and support software development including an app and a planned roll-out to London later this year.

Participated · Seed · Mar 2022

Jude builds products and services focused on bladder health, initially targeting women. Its core offering is a non-prescription bladder-strength supplement (pumpkin seed extract and soy germ extract) sold alongside absorbent pants, liners and pads. Jude operates a free support hotline staffed by trained specialists, a pelvic-floor exercise plan and a 4,000-member community; it also has a medical board and some in-house GPs. The company launched in the U.K. in January last year and has reached about 18,000 customers so far, projecting 4x U.K. usage in 12 months and roughly 100,000 customers next year as it expands to the U.S. Jude plans a digital consultation service and is applying for a U.K. medical licence for its supplement while pursuing patents and further studies to deepen product defensibility. The team intends to add more medical expertise (urologists/doctors) over time and to broaden its digital proposition and research partnerships. Jude builds consumer bladder-care products including fully biodegradable, 100% plant-based liners and pads alongside clinically tested bladder-strength supplements. Launched in January 2022 by founder Peony Li, the platform aims to destigmatise bladder issues and create a community around incontinence. The company has already shipped products to 2,600 customers. Jude recently raised £2 million in a pre-seed round to fund growth. Planned uses of capital include R&D to further develop affordable bladder-care solutions, running large-scale clinical supplements trials, expanding the marketing team, and producing educational content to break down taboos. The company positions its supplements as clinically tested formulations using botanicals shown to improve bladder care and associated wellbeing.

Led · Series A · Oct 2020

Your.MD is a London-based creator of the medical-grade, augmented intelligence self-care app Healthily. Founded in 2015 and led by CEO Matteo Berlucchi, the company combines augmented intelligence with medically validated information to deliver personalized health tools and support. Healthily gives individuals relevant health resources to enable self-care when appropriate, all in one place. In September the company introduced its first co-branded app in India with Dettol to help consumers take control of their health. The company raised $30m in Series A funding from Reckitt Benckiser. The investment will enable expansion across markets including the UK, India and the US. Your.MD operates an AI-driven “pre-primary care” service delivered through a conversational bot and available on web, iOS, Android, Facebook Messenger, Skype, Slack and Telegram. The product combines a symptom‑drilling chatbot with a next‑generation search engine that surfaces detailed, verified information on medical conditions. The company has also built the OneStop Health platform, a marketplace of trusted health service providers and products, with commercial partnerships (examples include Push Doctor and Urban Massage). There are currently 35 international and local digital health businesses on the OneStop platform, and the company plans to grow this to over 100 by the end of the year. OneStop is central to the company’s monetization strategy for what is otherwise a free information service. To date, Your.MD has 2.1 million downloads and reports nearly a million monthly active users, with a reported user base that is 67% male and 33% female. Your.MD offers a smartphone ‘smart health assistant’ that uses AI and machine learning plus licensed NHS data to give users information about conditions, likely causes and recommended next steps, including when to see a doctor. The app is positioned as an alternative to services such as NHS 111 and competitors like Symptomate, WebMD and Google Doctor. CEO Matteo Berlucchi says the product aims to act as a first-line, scalable alternative to waiting for doctor appointments by training AI to ask clinician-like questions and continuously learn from symptom patterns. The company says the system improves by correlating user symptoms and location data (for example, detecting local flu patterns). The app is free to users today, and the startup is eyeing value-added services such as the option to talk to a doctor, access more specialized information, and book tests. The company is London-based and emphasizes scalability through automation rather than relying on scarce clinical resources.

Led · Equity · Sep 2020

Pharmapacks provides a proprietary technology platform that delivers logistics, fulfillment, marketing and sales services to brands selling on marketplaces such as Amazon, Walmart, Google, eBay and Facebook. The platform is designed to enable brands to focus on product research and development while Pharmapacks handles marketplace operations. The company is led by CEO Andrew Vagenas and employs 850 people. Pharmapacks operates as both an ecommerce enablement provider and a retail seller for brands. The article does not disclose revenue or other financial metrics beyond recent financings. Pharmapacks operates a proprietary e-commerce technology platform that provides logistics, fulfillment, marketing and sales solutions for brands on marketplaces such as Amazon, Walmart, Google, eBay and Facebook. The company serves as a launch pad for emerging and lesser-known brands by providing access to its platform and consumer base while brands focus on product R&D. Led by CEO Andrew Vagenas, Pharmapacks employs a team of eCommerce experts with over 10 years' experience and ~850 employees. The company reached over $250M in sales in 2019 and was on a run rate to achieve more than 70% year-over-year growth, with an expectation of 100% year-over-year growth in Q4 after opening a 230k sq ft replenishment center in late Q3. Pharmapacks intends to use the financing to accelerate its expansion plans. Pharmapacks operates a proprietary e-commerce technology platform that helps brands reach consumers through logistics, fulfillment, marketing and sales. The company sells direct-to-consumer via Pharmapacks.com and through online marketplaces including Amazon, Walmart.com and eBay. It runs a 140,000 square foot warehouse in Islandia, New York, maintains an in-house technology team building automated assistance tools, and partners with Sealed Air on the I-Pack® system. Pharmapacks’ catalog comprises 28,000 unique items and the business processes and ships over 30,000 orders per day to all 50 U.S. states and Canada. The company employs about 350 people and plans to grow that headcount by 20 percent, scale its warehouse, advance automation and expand inventory and delivery reach into Europe, Asia and beyond.